Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R38 | P59533 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2048357 | 0.76 | — | — | |
| SCHEMBL711912 | 0.76 | HSP90AA1 (0.38) | TAS2R38 | |
| SCHEMBL12216285 | 0.74 | HSP90AA1 (0.48) | TAS2R38 | |
| SCHEMBL1770382 | 0.72 | ALDH1A1 (0.35) | — | |
| SCHEMBL10336651 | 0.72 | — | — | |
| SCHEMBL12192250 | 0.70 | FFAR3 (0.32) | — | |
| SCHEMBL31118105 | 0.69 | EGLN1 (0.42) | — | |
| SCHEMBL23716964 | 0.65 | THRB (0.36) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30990370 | 0.64 | — | — | |
| SCHEMBL27850847 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497272-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497272-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110245262-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-10-06 | — | — | US | disclosed |
| US-20110245262-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245262-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | TAS2R38 4599/4885F2 4407/4885PRSS1 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.